Recent developments center on the DEA’s expedited administrative hearing, scheduled to begin June 29, 2026, which will evaluate moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. An April 2026 Department of Justice order already placed FDA-approved products and state-regulated medical marijuana into Schedule III, following a December 2025 executive order directing faster rulemaking. Traders are monitoring whether the hearing produces a final rule on broader rescheduling within targeted windows, alongside any procedural delays, public comments, or challenges that could extend the timeline. The process builds on HHS recommendations from 2023 and reflects ongoing administrative momentum toward reclassification while preserving controls on non-medical use.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$768,642 Vol.
31. März 2026
30. Juni
1%
31. Dezember
27%
$768,642 Vol.
30. Juni
$341,550 Vol.
1%
31. Dezember
$162,210 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the DEA’s expedited administrative hearing, scheduled to begin June 29, 2026, which will evaluate moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. An April 2026 Department of Justice order already placed FDA-approved products and state-regulated medical marijuana into Schedule III, following a December 2025 executive order directing faster rulemaking. Traders are monitoring whether the hearing produces a final rule on broader rescheduling within targeted windows, alongside any procedural delays, public comments, or challenges that could extend the timeline. The process builds on HHS recommendations from 2023 and reflects ongoing administrative momentum toward reclassification while preserving controls on non-medical use.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Volumen
$768,642Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the DEA’s expedited administrative hearing, scheduled to begin June 29, 2026, which will evaluate moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. An April 2026 Department of Justice order already placed FDA-approved products and state-regulated medical marijuana into Schedule III, following a December 2025 executive order directing faster rulemaking. Traders are monitoring whether the hearing produces a final rule on broader rescheduling within targeted windows, alongside any procedural delays, public comments, or challenges that could extend the timeline. The process builds on HHS recommendations from 2023 and reflects ongoing administrative momentum toward reclassification while preserving controls on non-medical use.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$768,642Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent developments center on the DEA’s expedited administrative hearing, scheduled to begin June 29, 2026, which will evaluate moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. An April 2026 Department of Justice order already placed FDA-approved products and state-regulated medical marijuana into Schedule III, following a December 2025 executive order directing faster rulemaking. Traders are monitoring whether the hearing produces a final rule on broader rescheduling within targeted windows, alongside any procedural delays, public comments, or challenges that could extend the timeline. The process builds on HHS recommendations from 2023 and reflects ongoing administrative momentum toward reclassification while preserving controls on non-medical use.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen